about
The Minnesota Health Partnership and coordinated health care and disability prevention: the implementation of an integrated benefits and medical care modelEVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorderAdditional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.Epigenetic activation of SOX11 in lymphoid neoplasms by histone modifications.Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma.Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells.Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia.Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas.Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia.Cytogenetic risk stratification in chronic myelomonocytic leukemia.LMO2 expression reflects the different stages of blast maturation and genetic features in B-cell acute lymphoblastic leukemia and predicts clinical outcome.The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromesLandscape of somatic mutations and clonal evolution in mantle cell lymphoma.Hypermethylation of the alternative AWT1 promoter in hematological malignancies is a highly specific marker for acute myeloid leukemias despite high expression levels.Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.Simultaneous translocations of FGFR3/MMSET and CCND1 into two different IGH alleles in multiple myeloma: lack of concurrent activation of both proto-oncogenes.De novo erythroleukemia chromosome features include multiple rearrangements, with special involvement of chromosomes 11 and 19.Frequent gain of chromosome 19 in megakaryoblastic leukemias detected by comparative genomic hybridization.High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma.Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription.Downregulation of specific miRNAs in hyperdiploid multiple myeloma mimics the oncogenic effect of IgH translocations occurring in the non-hyperdiploid subtype.Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer.CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia.Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms.A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.Amplification of ERBB2, RARA, and TOP2A genes in a myelodysplastic syndrome transforming to acute myeloid leukemia.Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome.Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas.CBL RING finger deletions are common in core-binding factor acute myeloid leukemias.Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma.Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities.Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.Cryptic ins(2;11) with clonal evolution showing amplification of 11q23-q25 either on hsr(11) or on dmin, in a patient with AML-M2.
P50
Q23918343-8BD908CA-D0F6-42B4-9090-F2CA970216ACQ24620267-378C8AEF-BCE4-4FFB-A007-20C2EF8CED86Q27312570-9C12DBEC-7D59-408B-B33A-86804DB1E3C9Q28256823-8379B88D-5138-4A83-A24F-3A56785AEAC7Q33707423-009E6E87-B299-4643-9D09-CBAEF847B965Q33954847-CA8B3368-6051-4089-B8B7-FE2D6363FCDEQ34112913-EFA01CC4-1D9B-410E-B575-CF8BB6CBB8F8Q34288682-8DEC8574-73EE-4F3D-9AB5-35177389CD72Q34327110-7BDD0517-8457-4BEF-BA2F-E1CBEDA25091Q34413839-1C55C293-CAA7-4310-969E-6C9FB0FDF9C8Q34460989-3D831B5C-B0C5-4852-A736-0684FCDD1AB2Q34471115-1A3619DC-E9B6-40E1-912E-514FCB1DC2D3Q34612592-B2208F59-540F-44F3-9D19-1E165816D212Q35082503-400DAB63-CF46-4159-AB09-3A9C639C0E5BQ35244865-B11029D2-A54E-472A-9002-E630ED0026C0Q37318226-68806DD9-801C-46C9-87D2-662CF3AB431AQ37510844-DBA1A56B-3AFA-4B72-A818-F758F19EBD96Q38107912-8AE23140-4A2D-4B68-98F8-19C2622FA7A9Q38327984-9B17394C-93DA-4AA9-BBAD-70984E466756Q38462508-18A3E46B-B081-40C8-8EAE-3DE2BC959FD7Q38485176-CA2AA34E-AB43-4973-861B-3F1EE34E8C90Q38491894-6FA461CF-06B4-4073-A94F-7C2D33C8BD0DQ39311207-1B7FF327-8891-46F5-8332-B8AAB0806C38Q39332914-B225340D-1173-48F3-B2D0-26FBFA3FF88BQ39515650-362BD166-32D1-4F78-BECB-7FE8E4C75720Q40543868-A828B267-8445-4467-96C2-EFFAA6E8D501Q42573854-C7974901-BBE8-4165-9150-1A64CFE2DA3CQ42583748-310E4854-9869-44EA-815B-277EB97A2A88Q43086317-6F2D0C81-CB3C-4421-A122-A7BB529DB193Q43100101-10E50E5F-5786-4C00-8205-F865F9F3CCECQ43443310-413DEB56-3178-41D6-B620-1D44B355FF50Q43652925-CD9D261E-DC9F-450C-989B-A420AA863140Q43770648-93CBC3F4-BEE1-46C9-A593-957193A95415Q44016601-1A3BEA7E-C4ED-4115-8C99-BD9CBD7B4199Q44076785-1FA82F9F-83F1-4B3F-923C-CE25FDCB3CDAQ44114704-A2CC8F11-0C27-42FE-9687-A4769F65CA07Q44287656-7F03DB40-3BE5-4568-A2BF-F8816AAED40FQ44666362-CFA40E06-AFEB-4860-9522-1664A4EFE924Q44893063-81575B94-641B-47EF-BF60-666B5F852FDBQ45106457-BAEA1532-3D6C-4D8E-8D67-7DA74078891D
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
M J Calasanz
@ast
M J Calasanz
@en
M J Calasanz
@es
M J Calasanz
@nl
type
label
M J Calasanz
@ast
M J Calasanz
@en
M J Calasanz
@es
M J Calasanz
@nl
prefLabel
M J Calasanz
@ast
M J Calasanz
@en
M J Calasanz
@es
M J Calasanz
@nl
P31
P496
0000-0002-0374-3008